NCT05669599: An ongoing trial by Amgen
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05669599 |
|---|---|
| Title | A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 18, 2023 |
| Completion date | Oct. 8, 2024 |
| Required reporting date | Oct. 8, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |